Loading clinical trials...

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

A Single-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2, Dose Ranging Evaluation of the Effectiveness of Bilastine Ophthalmic Solution (0.2%, 0.4%, and 0.6%) Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model

NCT03231969•Faes Farma, S.A.

View on ClinicalTrials.gov

Summary

To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•be at least 18 years old
•be willing and able to avoid all disallowed medications and contact lenses
•must have a pregnancy test if of childbearing potential
•must be able to read an eye chart from 10 feet away

Exclusion Criteria

•must not have any allergies to the study medications
•must not have any ocular or non ocular condition that investigator feels will interfere with study parameters
•must not have used immunotherapy in the last 2 years
•must not have used an investigational drug or device in the past 30 days or concurrently enrolled in another investigational trial

Locations (1)

Ora Clinical Research Center

Andover, Massachusetts, United States

Key Dates

Start Date

July 20, 2017

Primary Completion Date

October 11, 2017

Completion Date

October 11, 2017

Last Updated

March 16, 2023

Enrollment

121

ACTUAL participants

Conditions

Allergic Conjunctivitis

Interventions

Bilastine 0.2%

DRUG

Bilastine 0.4%

DRUG

Bilastine 0.6%

DRUG

Bilastine 0%

DRUG

The Role of Vitamin D in Corneal Epithelial Barrier Function, Ocular Microbiome, Ocular Inflammation, and Visual Acuity of Children With Allergic Conjunctivitis

NCT05839938

Allergic Conjunctivitis

View study

ACTIVE_NOT_RECRUITING

Tyrosine Allergoid Paediatric and Adult Study

NCT05186025

Allergic Rhinitis Due to PollenAllergic Conjunctivitis+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 16, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

Inclusion Criteria

Exclusion Criteria

The Role of Vitamin D in Corneal Epithelial Barrier Function, Ocular Microbiome, Ocular Inflammation, and Visual Acuity of Children With Allergic Conjunctivitis

Tyrosine Allergoid Paediatric and Adult Study

Documentation of Efficacy of Intralymphatic Allergen Immunotherapy

Clinical and Biological Evaluation of NAAGA Versus Azelastine Eye Drops in Allergic Subjects With Tear Film Dysfunction

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

Dietary Choice for the Management of Cow's Milk Allergy Influences Other Allergic Manifestations